| Objective:Pomalidomide plays an important role in anti-tumor,anti-angiogenesis and immune regulation.The purpose of this study was to systematically evaluate the efficacy and safety of different drugs regimens based on pomalidomide in the treatment of Relapsed Refractory Multiple Myeloma(RRMM).Methods:The computer comprehensively searched the literature about pomalidomide in the treatment of RRMM,and the search results were not limited by any geographical region or race.The data consistent with the research topic were extracted and meta analyzed.The observation indicators include the Overall Reaction Rate(ORR)and the incidences of grade?3 adverse events(AE).Results:A total of 23 studies were included.The results showed that in all the triple drug combinations based on pomalidomide,the ORR was 64.3%[95%CI(57.5,71.1)]and I~2was 89.2%.The results of stratified analysis were as follows:pomalidomide,dexamethasone,bortezomib(PVD)(82.8%),pomalidomide,dexamethasone,cyclophosphamide(PCD)(65.2%),pomalidomide,dexamethasone,daratumumab(58.7%),pomalidomide,dexamethasone,Isatuximab(60.8%),pomalidomide,dexamethasone,clarithromycin(ClaPd)(59.8%),pomalidomide,dexamethasone,adriamycin(PLD)(35.2%),pomalidomide,dexamethasone,carfilzomib(71.9%);Incidences of grade?3 hematological toxicity is mainly neutropenia(54.5%),thrombocytopenia(18.1%),anemia(19.1%),incidences of grade?3 non-hematological toxicity are mainly infection(6.0%),pneumonia(12.3%)and fatigue(15.4%).Conclusion:In RRMM,the total ORR of pomalidomide-based triple drug regimen(64.3%)was twice as high as that of pomalidomide alone combined with dexamethasone(35.7%),among which PVD and pomalidomide,dexamethasone combined with carfilzomib were more effective.However,because there are some limitations in the number of studies and treatments,and the conclusions of cross-control trials are uncertain,the conclusions of this paper need to be further confirmed by a large number of prospective studies. |
PDF Full Text Request